Previous 10 | Next 10 |
Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules ) Data support s a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumor s (NET) Global ...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Amryt Pharma plc (“Amryt Pharma” or the “Company”) (NASDAQ: AMYT) on behalf of Amryt Pharma stockholders. Our investigation concern...
The law firm of Kirby McInerney LLP is investigating potential claims against Amryt Pharma plc (“Amryt Pharma” or the “Company”) (NASDAQ: AMYT ). The investigation concerns whether Amryt Pharma has violated the federal securities laws and/or engaged i...
Results of General Meeting Share-Repurchase Program Form of Contract and Counterparties Approved DUBLIN, Ireland, and Boston MA, March 3, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializin...
NEW YORK, NY / ACCESSWIRE / March 2, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amryt Pharma plc (" Amryt " or the "Company") (NASDAQ:AMYT) . Investors who purchased Amryt securities are encouraged to obtain ad...
Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...
Shares of Amryt Pharma (NASDAQ:AMYT) are down 20% after the U.S. FDA issued the company a Complete Response Letter for its New Drug Application for Oleogel-S10 to treat a rare, genetic skin disease. Amryt is seeking approval of Oleogel-S10 cutaneous manifestations of Dystrophic and Junctional...
Gainers: IntriCon (NASDAQ:IIN) +37%. NeuroSense Therapeutics (NASDAQ:NRSN) +28%. Homology Medicines (NASDAQ:FIXX) +17%. CorMedix (NASDAQ:CRMD) +14%. Reata Pharmaceuticals (NASDAQ:RETA) +13%. Losers: Aurinia Pharmaceuticals (NASDAQ:AUPH) -29%. Lexicon Pharmac...
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 N D A DUBLIN, Ireland, and B oston , MA, February 28 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, deve...
100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...